Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites.

Mu L, Zhou R, Tang F, Liu X, Li S, Xie F, Xie X, Peng J, Yu P.

Acta Pharm Sin B. 2016 Mar;6(2):158-62. doi: 10.1016/j.apsb.2015.10.002. Epub 2015 Dec 21.

2.

Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.

Kasirye RP, Baisley K, Munderi P, Levin J, Anywaine Z, Nunn A, Kamali A, Grosskurth H.

AIDS. 2016 Feb 20;30(4):635-44. doi: 10.1097/QAD.0000000000000956.

3.

Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats.

Kumar P, Lakshmi YS, C B, Golla K, Kondapi AK.

PLoS One. 2015 Oct 13;10(10):e0140399. doi: 10.1371/journal.pone.0140399. eCollection 2015.

4.

Hematological Indices at Birth of Infants of HIV-Positive Mothers Participating in a Prevention of Mother-to-Child Transmission Program.

Obumneme-Anyim I, Ibeziako N, Emodi I, Ikefuna A, Oguonu T.

J Trop Pediatr. 2016 Feb;62(1):3-9. doi: 10.1093/tropej/fmv061. Epub 2015 Sep 27.

PMID:
26411560
5.

Prevalence and correlates of anemia among HIV infected patients on highly active anti-retroviral therapy at Zewditu Memorial Hospital, Ethiopia.

Assefa M, Abegaz WE, Shewamare A, Medhin G, Belay M.

BMC Hematol. 2015 Apr 30;15:6. doi: 10.1186/s12878-015-0024-6. eCollection 2015.

6.

Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration.

Abo Y, Zannou Djimon M, Messou E, Balestre E, Kouakou M, Akakpo J, Ahouada C, de Rekeneire N, Dabis F, Lewden C, Minga A; IeDEA West Africa Collaboration.

BMC Infect Dis. 2015 Apr 9;15:176. doi: 10.1186/s12879-015-0910-3.

7.

High Incidence of Zidovudine Induced Anaemia in HIV Infected Patients in Southern Odisha.

Dash KR, Meher LK, Hui PK, Behera SK, Nayak SN.

Indian J Hematol Blood Transfus. 2015 Jun;31(2):247-50. doi: 10.1007/s12288-014-0426-9. Epub 2014 Sep 28.

8.

Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa.

Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker LG, Lawn SD.

BMC Infect Dis. 2014 Dec 21;14:3860. doi: 10.1186/s12879-014-0702-1.

9.

Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.

Parkes-Ratanshi R, Katende D, Levin J, Wakeham K, Heiner G, Kamali A, Lalloo DG.

J Int Assoc Provid AIDS Care. 2015 Sep-Oct;14(5):455-62. doi: 10.1177/2325957414557264. Epub 2014 Nov 25.

10.

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.

Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, McIlleron H, Lienhardt C, Pym A.

BMC Pharmacol Toxicol. 2014 Nov 19;15:61. doi: 10.1186/2050-6511-15-61.

11.

Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon.

Bekolo CE, Sonkoue C, Djidjou H, Bekoule PS, Kollo B.

BMC Infect Dis. 2014 Sep 25;14:519. doi: 10.1186/1471-2334-14-519.

12.

Neutropenia during HIV infection: adverse consequences and remedies.

Shi X, Sims MD, Hanna MM, Xie M, Gulick PG, Zheng YH, Basson MD, Zhang P.

Int Rev Immunol. 2014 Nov-Dec;33(6):511-36. doi: 10.3109/08830185.2014.893301. Epub 2014 Mar 21. Review.

13.

Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India.

Shet A, Antony J, Arumugam K, Kumar Dodderi S, Rodrigues R, DeCosta A.

PLoS One. 2014 Mar 10;9(3):e91028. doi: 10.1371/journal.pone.0091028. eCollection 2014.

14.

Haemoglobin recovery among HIV-1 infected patients on zidovudine-based antiretroviral therapy and other regimens in north-central Nigeria.

Parrish DD, Blevins M, Megazzini KM, Shepherd BE, Mohammed MY, Wester CW, Vermund SH, Aliyu MH.

Int J STD AIDS. 2014 Apr;25(5):355-9. doi: 10.1177/0956462413506887. Epub 2013 Oct 8.

15.

Biochemical and haematological changes in HIV subjects receiving winniecure antiretroviral drug in Nigeria.

Ibeh BO, Omodamiro OD, Ibeh U, Habu JB.

J Biomed Sci. 2013 Oct 7;20:73. doi: 10.1186/1423-0127-20-73.

16.

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.

Dryden-Peterson S, Jayeoba O, Hughes MD, Jibril H, McIntosh K, Modise TA, Asmelash A, Powis KM, Essex M, Shapiro RL, Lockman S.

PLoS One. 2013 Sep 23;8(9):e74171. doi: 10.1371/journal.pone.0074171. eCollection 2013.

17.

Neutropenia in HIV-Infected Kenyan Women Receiving Triple Antiretroviral Prophylaxis to Prevent Mother-to-Child HIV Transmission Is Not Associated with Serious Clinical Sequelae.

Iuliano AD, Weidle PJ, Brooks JT, Masaba R, Girde S, Ndivo R, Ogindo P, Omolo P, Zeh C, Thomas TK.

J Int Assoc Provid AIDS Care. 2015 May-Jun;14(3):261-8. doi: 10.1177/2325957413502543. Epub 2013 Sep 30.

18.

Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria.

Agu KA, Oparah AC.

Perspect Clin Res. 2013 Apr;4(2):117-24. doi: 10.4103/2229-3485.111784.

19.

Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.

Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, Carrou JL, Bohoussou F, Eholie SP, Anglaret X.

J Int AIDS Soc. 2013 Apr 30;16:18059. doi: 10.7448/IAS.16.1.18059.

20.

Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.

Phe T, Thai S, Veng C, Sok S, Lynen L, van Griensven J.

PLoS One. 2013;8(3):e60206. doi: 10.1371/journal.pone.0060206. Epub 2013 Mar 26.

Items per page

Supplemental Content

Write to the Help Desk